The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Identifying patients with NTRK fusion cancer
Open accessAbstract
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer. These oncogenic fusions occur when the kinase domain of NTRK1, NTRK2 or NTRK3 fuse with any of a number of N-terminal partners. NTRK fusions are characteristic of a few rare types of cancer, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, but they are also infrequently seen in some common cancers, such as melanoma, glioma and carcinomas of the thyroid, lung and colon. There are multiple methods for identifying NTRK fusions, including pan-TRK immunohistochemistry, fluorescence in situ hybridisation and sequencing methods, and the advantages and drawbacks of each are reviewed here. While testing algorithms will obviously depend on availability of various testing modalities and economic considerations for each individual laboratory, we propose triaging specimens based on histology and other molecular findings to most efficiently identify tumours harbouring these treatable oncogenic fusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 2×
“because of the aforementioned issues involving coverage of the NTRK3 introns, fusions involving NTRK3 other than ETV6, are not covered by the assay [25, 28, 37].”
BackgroundSelf-citationEfficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationNTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Kaplan, D. R., Martin-Zanca, D., & Parada, L. F. (1991) · Nature · doi:10.1038/350158a0 · Cited by 1,055
Skálová, A., Vanecek, T., Sima, R., Laco, J., Weinreb, I., Perez-Ordonez, B., Starek, I., Geierova, M., Simpson, R. H., Passador-Santos, F., et al. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,023
Anchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Soppet, D., Escandon, E., Maragos, J., Middlemas, D. S., Raid, S. W., Blair, J., Burton, L. E., Stanton, B. R., Kaplan, D. R., Hunter, T., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90396-g · Cited by 820
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
Martin-Zanca, D., Hughes, S. H., & Barbacid, M. (1986) · Nature · doi:10.1038/319743a0 · Cited by 803
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
Knezevich, S. R., McFadden, D. E., Tao, W., Lim, J. F., & Sorensen, P. H. B. (1998) · Nature Genetics · doi:10.1038/ng0298-184 · Cited by 800
Cited by
Update on Fundamental Mechanisms of Thyroid Cancer
Prete, A., Borges de Souza, P., Censi, S., Muzza, M., Nucci, N., & Sponziello, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00102 · Cited by 471
Management of Salivary Gland Malignancy: ASCO Guideline
Geiger, J. L., Ismaila, N., Beadle, B., Caudell, J. J., Chau, N., Deschler, D., Glastonbury, C., Kaufman, M., Lamarre, E., Lau, H. Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00449 · Cited by 441
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 266
Gupta, R., Dittmeier, M., Wohlleben, G., Nickl, V., Bischler, T., Luzak, V., Wegat, V., Doll, D., Sodmann, A., Bady, E., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00809-0 · Cited by 7
Metadata
- Authors
- Solomon, J. P., Benayed, R., Hechtman, J. F., & Ladanyi, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 30
- Issue
- Suppl_8
- Pages
- viii16-viii22
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2988542587
- Cited by
- 270
- References
- 47
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identifying patients with NTRK fusion cancer. https://app.cochat.ai/papers/10.1093/annonc/mdz384
- The paper
- Solomon, J. P., Benayed, R., Hechtman, J. F., & Ladanyi, M. (2019). Identifying patients with NTRK fusion cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdz384
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.